- Home
- DBI vs ACIU Comparison
DBI vs ACIU Comparison
Compare DBI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- ACIU
- Stock Information
- Founded
- DBI 1991
- ACIU 2003
- Country
- DBI United States
- ACIU Switzerland
- Employees
- DBI N/A
- ACIU N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- DBI Consumer Discretionary
- ACIU Health Care
- Exchange
- DBI Nasdaq
- ACIU Nasdaq
- Market Cap
- DBI 292.2M
- ACIU 332.4M
- IPO Year
- DBI 1991
- ACIU 2016
- Fundamental
- Price
- DBI $5.55
- ACIU $2.71
- Analyst Decision
- DBI Hold
- ACIU Strong Buy
- Analyst Count
- DBI 2
- ACIU 2
- Target Price
- DBI $5.75
- ACIU $12.00
- AVG Volume (30 Days)
- DBI 2.1M
- ACIU 132.5K
- Earning Date
- DBI 12-10-2024
- ACIU 11-05-2024
- Dividend Yield
- DBI 3.68%
- ACIU N/A
- EPS Growth
- DBI N/A
- ACIU N/A
- EPS
- DBI N/A
- ACIU N/A
- Revenue
- DBI $3,050,038,000.00
- ACIU $48,505,404.00
- Revenue This Year
- DBI N/A
- ACIU $85.33
- Revenue Next Year
- DBI $2.23
- ACIU $80.69
- P/E Ratio
- DBI N/A
- ACIU N/A
- Revenue Growth
- DBI N/A
- ACIU 4097200.00
- 52 Week Low
- DBI $4.36
- ACIU $2.25
- 52 Week High
- DBI $11.57
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- DBI 46.98
- ACIU 27.22
- Support Level
- DBI $5.18
- ACIU $2.63
- Resistance Level
- DBI $6.21
- ACIU $3.07
- Average True Range (ATR)
- DBI 0.43
- ACIU 0.15
- MACD
- DBI -0.05
- ACIU -0.04
- Stochastic Oscillator
- DBI 42.47
- ACIU 8.96
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.